Iris Breitkreutz

Salem, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

Journal: Journal for immunotherapy of cancer
Published: September 08, 2024

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.

Journal: Blood cancer journal
Published: May 14, 2024

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case report.

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case report.

Journal: EJHaem
Published: August 02, 2022

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.

Journal: Cancers
Published: August 05, 2021

Erratum to: First-line treatment of multiple myeloma

Erratum to: First-line treatment of multiple myeloma

Journal: Der Internist
Published: March 20, 2019

First-line treatment of multiple myeloma

First-line treatment of multiple myeloma

Journal: Der Internist
Published: December 16, 2018

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Journal: Annals of hematology
Published: April 02, 2017

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Journal: Hematological oncology
Published: October 13, 2014

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Journal: Oncotarget
Published: July 15, 2014

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.

Journal: Bone marrow transplantation
Published: February 28, 2014

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

Journal: Cancer research
Published: September 04, 2012
Showing 1-11 of 11

Last Updated: 09/26/2026